Instrument Inactif

Autres langues NeoStem Inc NYSE

Actions

NBS

US6406503051

Recherche biotechnologique et médicale

Cours en clôture NYSE
- ^USD	-

06/08	Lisata Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
04/08	Lisata Therapeutics, Inc. poursuit l'évaluation d'alternatives stratégiques pour accroître la valeur actionnariale	CI

Autres langues

06/08	Lisata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Lisata Therapeutics, Inc. Continues to Evaluate Strategic Alternatives to Enhance Stockholder Value
04/08	Lisata Therapeutics Provides Update Following Termination of Merger Agreement
04/08	Lisata Therapeutics, Inc. Implements a Reduction in Force, Eliminating Approximately 72% of Full-Time Employees
24/07	Lisata Therapeutics Shares Fall After Terminating Kuva Labs Deal
21/07	Kuva Labs, Inc. cancelled the acquisition of Lisata Therapeutics, Inc..
15/06	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
10/06	Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
29/05	Lisata Therapeutics - amends merger offer price to $4 per share plus CVR
11/05	Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
12/03	Lisata Therapeutics : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)
12/03	Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
12/03	Lisata Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
07/03	Lisata Therapeutics enters into definitive agreement to be acquired by Kuva Labs, Inc.
07/03	Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
27/01	Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
27/01	Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
21/01	Top Midday Gainers
21/01	Kuva Labs, Inc. entered into a binding term sheet to acquire Lisata Therapeutics, Inc. for $38.9 million.
21/01	Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share in an all-cash tender offer
21/01	Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
06/11	Lisata Therapeutics : Earnings Release (lisata therapeutics reports third quarter 2025 financial results)
06/11	Lisata Therapeutics Q3 net loss narrows to $4.2 mln
06/11	Lisata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
06/11	Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update